Time is Brain: New ICH Guidelines Highlight the Urgency of Early Intervention
The 16th World Stroke Congress (WSC) 2024 brought exciting news for the treatment of intracerebral hemorrhage (ICH), a type of stroke involving bleeding within the brain. Several groundbreaking studies presented at the congress are poised to revolutionize ICH guidelines, emphasizing the crucial role of early intervention.
Minimally Invasive Surgery Shows Promise
One standout study, the ENRICH trial published in The New England Journal of Medicine, demonstrated the effectiveness of minimally invasive surgery (MIS) in reducing hematoma volume. This approach, which uses specialized devices to remove blood clots, resulted in a significantly lower mortality rate (9.3% vs 18.0%) and improved functional outcomes compared to medical management alone.
Dr. Thorsten Steiner, professor of neurology at the University of Heidelberg, who led the last set of ESO intracerebral hemorrhage guidelines, highlighted the significance of this finding. He anticipates that MIS will be included in the upcoming guidelines as a recommended option for hematoma evacuation.
Decompression Craniotomy for Deep ICH
Another promising study, the SWITCH trial, found that decompression craniotomy, a surgical procedure to relieve pressure on the brain, improved functional outcomes for patients with deep, severe ICH involving the basal ganglia or thalamus. While the trial was stopped early due to funding limitations, the results were compelling.
Dr. Steiner suggests that the new guidelines will recommend decompression craniotomy as a potentially beneficial option for selected patients with deep, severe ICH, stressing the importance of an interdisciplinary decision-making process involving families and, when possible, patients.
Early Treatment Key to Improving Outcomes
Across multiple studies, a consistent message emerged: early treatment is crucial for improving ICH outcomes.
The ANNEXA-1 trial demonstrated the benefits of reversing blood thinners in patients who had taken a factor Xa inhibitor within 15 hours of an ICH. Similarly, the INTERACT4 trial showed that early blood pressure control in suspected stroke patients, even before a definitive diagnosis, could reduce hematoma expansion and lead to better outcomes for those with ICH.
Tranexamic Acid: Timing Matters
While the STOP-MSU study did not support the use of early tranexamic acid (TA) in ICH, it did not negate the benefits of routine TA use based on other positive trials.
The Bottom Line: Time is Brain
Dr. Santiago Ortega-Gutiérrez, principal investigator at the Cerebrovascular & Neurointerventional Lab at the University of Iowa, echoed the importance of prompt treatment, stating, "Time is brain." He emphasized that the delay in releasing updated ICH guidelines allows for further data to solidify this message.
For more information about ICH and treatment options, visit the American Stroke Association website at [link to website].